Who is sponsoring NCT05635032?

NCT05635032 is sponsored by Universidade do Porto.

What drugs are being tested in NCT05635032?

Interventions in NCT05635032: Comprehensive clinical assessment and biological samples collection.

What condition does NCT05635032 study?

NCT05635032 studies Pulmonary Fibrosis, Sarcoidosis.

Is NCT05635032 still recruiting?

NCT05635032 is currently status unknown. Last updated 27 October 2023.

Last reviewed 2023-10-27 · How we verify

NCT05635032: FIBRALUNG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fibrosing ILD Biomarkers That Rule Acceleration

Status unknown Last updated 27 October 2023

What this trial tests

trial testing Comprehensive clinical assessment and biological samples collection in Pulmonary Fibrosis in 150 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
29 February 2024

31 March 2026

Quick facts

Lead sponsor	Universidade do Porto
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 March 2021
Primary completion	29 February 2024
Estimated completion	31 March 2026
Sites	1 location across Portugal

Drugs / interventions tested

Comprehensive clinical assessment and biological samples collection

Conditions studied

Pulmonary Fibrosis — all drugs for Pulmonary Fibrosis →
Sarcoidosis — all drugs for Sarcoidosis →

Sponsor

Universidade do Porto — full company profile →

Who can join

Adults 18 to 80, any sex, with Pulmonary Fibrosis or Sarcoidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

FIBRALUNG is a prospective cohort study with biobank of samples from patients with pulmonary fibrosis, aiming to explore the molecular determinants of different clinical outcomes, acute exacerbations and mortality. We expect to gain deeper insight into fibroproliferative common pathways, particularly between idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis, paving the way for new biomarkers that reflect the progressive phenotype, that eventually will support new targeted therapies. Other idiopathic interstitial pneumonias, connective tissue disease-related interstitial lung diseases and sarcoidosis patients will be also recruited and their biological samples stored for further analyses.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Spatial transcriptomics reveals altered communities and drivers of aberrant epithelia and pro-fibrotic fibroblasts in interstitial lung diseases.
Jaiswal A, Kooistra T, Pokatayev V, Bastos HN, et al · · 2026 · PMID 41576947 · DOI 10.1016/j.xgen.2025.101066

Verify or expand the search:

Other recruiting trials for Pulmonary Fibrosis

Currently open trials in the same condition.

NCT07464132 — Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases · Phase 1, PHASE2 · recruiting
NCT07396467 — Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis · active not recruiting
NCT06912659 — The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis W · active not recruiting
NCT06685874 — Interstitial Lung Disease Exacerbations Study · active not recruiting
NCT06532071 — Advanced Imaging for Pulmonary Fibrosis · Phase 2 · recruiting

Other Universidade do Porto trials

Trials by the same sponsor.

NCT07457697 — MyGENESIS: A Digital Psychoeducational Program for Donor-Conceived Young Adults · NA · not yet recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07436091 — Porcine Derma for Soft Tissue Augmentation Around Implants · NA · not yet recruiting
NCT07498556 — Immediate Restoration of a New Implant With High Primary Stability · NA · not yet recruiting
NCT07448870 — Evaluating the Mentalization-based Treatment Lighthouse Parenting Programme: Protocol of a Feasibility and Acceptability · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05635032 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidade do Porto
Last refreshed: 27 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05635032.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing